Oncology

Using the genome editing tool known as CRISPR, researchers were able to selectively silence two genes in HPV that are responsible for the growth and survival of cervical carcinoma cells.

The approval follows results from the RETRIEVE trial, conducted in patients who had previously responded to Velcade but had relapsed.

Although the overall rate of NSCLC is lower, certain subtypes of the disease fared better than others, the study published in the journal Cancer found.

New research found that the risk of developing breast cancer increased in women who had mutations of a gene related to BRCA2, the PALB2 gene.

The research, published in the journal Cell, proposes revising treatment based on the molecular constitution of the tumor when it presents itself, rather than the tissue or organ of origin.

According to Sir Andrew Dillon, chief executive of NICE, the high price that Roche is demanding for Kadcyla is beyond the means of NHS to cover.

The study, published in NEJM, proposes enhanced surveillance in women with PALB2 mutations, similar to women harboring BRCA2 mutations.

High rate of hospice survivors, especially in Alabama and Mississippi, have raised doubts about improper practices.

Published in Nature Communications, the study identified a new gene fusion and rearrangement of the estrogen receptor, responsible for the aggressive nature of luminal B breast cancer.

The Lancet study, conducted in Europe, found a survival benefit with early diagnosis, but does not agree that the benefit outweighs some of the associated risks of the test.

The results of ruxolitinib's RESPONSE trial were recently presented at ASCO's annual meeting.

Amy Berman, BS, RN, senior program officer at the John A. Hartford Foundation, says that the triple aim promotes better health, better care, and lower costs. All too often, however, current oncology treatment regimens do not achieve the triple aim.

Within a week of Sandoz applying for approval of it's biosimlar to Amgen's Neupogen, U.S. senators want the FDA to lay down guidelines on naming these drugs.

The study evaluated carfilzomib in combination with Celgene's lenalidomide and dexamethasone.

ABT-414 is being developed to treat glioblastoma multiforme.

Today, the U.S. Food and Drug Administration took important steps to ensure that certain tests used by health care professionals to help diagnose and treat patients provide accurate, consistent and reliable results.

The study, published in the journal Cell, was conducted at the Whitehead Institute of Biomedical Research.

While Incyte and Genentech announced partnership to study each of their immunooncology molecules in NSCLC, AstraZeneca and Kyowa Hakko Kirin signed a similar agreement to evaluate their candidate molecules in multiple solid tumors.

Dr Koss refused preoperative chemotherapy to avoid damaging her virulent cells, which could later be cultured and could likely provide therapeutic leads.

The authors observed that an artificial switch in cancer cells from an epithelial to a mesenchymal phenotype induced the expression of GLUT3, a protein that promotes cellular glucose uptake.

Molecular analysis is now underway to characterize subsets of patients who performed better or worse on either treatment.

The recommendation to the EMA came soon after Zydiga (idelalisib) was approved in the US.

The drug is to be administered right before chemotherapy or radiation, to bind to and inhibit cell division in normal cells and reduce the adverse effects of chemotherapy.

AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

New trial data confirms its use as standard therapy for CLL.

HIV-positive individuals are not usually enrolled in clinical trials, resulting in a knowledge-gap on their treatment options.

Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.

Following the success of robotics in prostate surgeries, the technique was expected to provide comparable results for bladder cancer surgeries as well.

Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.